2467 PUBLICATIONS
ANNÉE
JOURNAL
PREMIER AUTEUR
TITRE
ANNÉE2022
JOURNALJournal of personalized medicine
PREMIER AUTEURCherkaoui Z
TITREEvaluation of an Innovative Care Pathway in the Diagnostic and Therapeutic Management of Hepatobiliary and Pancreatic Pathologies: "One-Day Diagnosis".
ANNÉE2022
JOURNALGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
PREMIER AUTEURVenkatasamy A
TITREMorpho-functional analysis of patient-derived xenografts reveals differential impact of gastric cancer and chemotherapy on the tumor ecosystem, affecting immune check point, metabolism, and sarcopenia.
ANNÉE2022
JOURNALCancers
PREMIER AUTEURHergalant S
TITRECorrelation between DNA Methylation and Cell Proliferation Identifies New Candidate Predictive Markers in Meningioma.
ANNÉE2022
JOURNALBMC cancer
PREMIER AUTEURBruand M
TITREAcute skin toxicity of conventional fractionated versus hypofractionated radiotherapy in breast cancer patients receiving regional node irradiation: the real-life prospective multicenter HYPOBREAST cohort.
ANNÉE2022
JOURNALFrontiers in oncology
PREMIER AUTEURNeuville C
TITRENivolumab-induced capillary leak syndrome associated with chylothorax in a melanoma patient: A case report and review of the literature.
ANNÉE2022
JOURNALFrontiers in oncology
PREMIER AUTEURDardare J
TITREDDB2 represses epithelial-to-mesenchymal transition and sensitizes pancreatic ductal adenocarcinoma cells to chemotherapy.
ANNÉE2022
JOURNALFrontiers in oncology
PREMIER AUTEURSpira A
TITREIdentification of as a predictive biomarker of response to bintrafusp alfa in a phase 1 trial in patients with advanced triple-negative breast cancer.
ANNÉE2022
JOURNALBiochimica et biophysica acta. Molecular basis of disease
PREMIER AUTEURLirussi F
TITREPlasma membrane lipid bilayer is druggable: Selective delivery of gemcitabine-squalene nano-medicine to cancer cells.
ANNÉE2022
JOURNALRadiation oncology (London, England)
PREMIER AUTEURDemogeot N
TITREImpact of fractionated stereotactic radiotherapy on activity of daily living and performance status in progressive/recurrent glioblastoma: a retrospective study.
ANNÉE2022
JOURNALFrontiers in immunology
PREMIER AUTEURBrisebarre A
TITRETranscriptomic FHIT/pHER2 signature as a predictive factor of outcome and immunotherapy response in non-small cell lung cancer.

Retrouvez aussi

Personnes
Equipes
Plateformes
Unités de recherche, établissements
Projets de recherche
Publications scientifiques